Cystic Fibrosis Clinical Trial
Official title:
The Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-oesophageal Function
Gastro-oesophageal reflux (GOR) has been found to be prevalent in children with cystic fibrosis (CF)and may further worsen lung damage via reflex bronchospasm or pulmonary aspiration. Chest physiotherapy may result in increased episodes of GOR as demonstrated in children. Lung transplantation may worsen pre-existing GOR. This study will determine the prevalence, severity and significance of symptomatic and silent GOR in adults with CF before and after lung transplant using 24hr oesophageal pH monitoring, a valid symptom questionnaire, quality of life questionnaires and gastric emptying studies. This study will identify the extent of GOR in a large adult CF population and the impact on lung function and quality of life together with the effects of medical and physiotherapy treatment on gastro-oesophageal function.
A factorial longitudinal study will be undertaken in adults with cystic fibrosis. Results
will be compared with age matched healthy controls. It is not deemed appropriate to
randomise patients with gastro-oesophageal reflux(GOR) to a treatment versus no treatment
group as immediate treatment for GOR once diagnosed is regarded as obligatory.
Subjects: 180 adults with CF will be recruited from the Adult Cystic Fibrosis Unit at the
Alfred Hospital to participate in the study. The ambulatory studies will be undertaken
during baseline state in the outpatient setting. Fifteen age matched control subjects will
be recruited from the general population.
Subjects who give their consent for participation in the study will undertake the following
outcome measures:
1. Demographic data including age, gender, BMI, prescribed medication at the time of the
study, lung function tests including FEV1, FVC, FEV1/FVC ratio and MMEF, genotype, pH
of saliva and sputum.
2. Structured symptom questionnaire using a reliable valid measure developed by Carlsson
et al 1998 will be used to assess patient's symptom scores.
3. Dual-channel 24hour oesophageal pH monitoring will be undertaken using a digitrapper
(Medtronic, Sweden)and dual antimony tipped probe (Synectics, Sweden). Following
calibration of the probes the distal antimony tip is positioned 5cm above the upper
border of the lower oesophageal sphincter and the proximal probe 15 cm above the distal
probe in the upper oesophagus.The patient will be instructed in using the three event
buttons on the digitrapper recording start and finish time of meals, upright versus
supine positioning and reflux episodes. The subject will be provided with a detailed
24hr 'Activity Diary' to record all meals (including percutaneous gastrostomy feeds),
positions and activities including usual chest physiotherapy and physical exercise.The
recorded pH information is downloaded into a computer program for analysis. The
following indices will be measured in the distal and proximal oesophagus:
- Number of reflux episodes
- Fraction of reflux time
- Number of reflux episodes with duration longer than 5 minutes
- Duration of longest episodes in minutes
- DeMeester score (an overall weighted score of gastro-oesophageal function).
4. Quality of life questionnaires: SF36, Quittner CF Questionnaire (CFQ), Dietary and
Bowel Symptom Questionnaires.
5. Chest radiographs
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |